Raub Brock Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.4M Sell
13,706
-4,866
-26% -$4.97M 4.53% 3
2026
Q1
$17.1M Sell
18,572
-2,608
-12% -$2.64M 4.32% 5
2025
Q4
$22.8M Sell
21,180
-720
-3% -$688K 5.07% 4
2025
Q3
$16.7M Sell
21,900
-223
-1% -$166K 3.6% 11
2025
Q2
$17.2M Sell
22,123
-547
-2% -$425K 3.76% 11
2025
Q1
$18.7M Sell
22,670
-1,340
-6% -$1.12M 4.18% 6
2024
Q4
$18.5M Buy
24,010
+131
+0.5% +$108K 3.94% 11
2024
Q3
$21.2M Sell
23,879
-734
-3% -$660K 4.3% 9
2024
Q2
$22.3M Sell
24,613
-3,691
-13% -$2.95M 4.87% 4
2024
Q1
$22M Sell
28,304
-3,773
-12% -$2.69M 4.66% 3
2023
Q4
$18.7M Sell
32,077
-12,536
-28% -$7.32M 3.92% 10
2023
Q3
$24M Sell
44,613
-2,144
-5% -$1.1M 4.76% 3
2023
Q2
$21.9M Sell
46,757
-17,047
-27% -$7.15M 4.12% 9
2023
Q1
$21.9M Buy
63,804
+1,769
+3% +$597K 4.21% 7
2022
Q4
$22.7M Sell
62,035
-6,865
-10% -$2.43M 4.64% 4
2022
Q3
$22.3M Sell
68,900
-4,367
-6% -$1.38M 4.65% 5
2022
Q2
$23.8M Buy
+73,267
New +$22M 4.53% 5

Other funds holding LLY

Raub Brock Capital Management's LLY Position: Q2 2026 in Review

Raub Brock Capital Management reduced its Eli Lilly (LLY) stake by 26% in Q2 2026, selling an estimated $4.97M and leaving 13,706 shares worth $16.4M. The position accounts for 4.53% of the portfolio, ranked #3.

Raub Brock Capital Management first reported a position in LLY in Q2 2022 and has held it in 17 quarters since. The position peaked at $24M in Q3 2023. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Raub Brock Capital Management held 13,706 shares of Eli Lilly worth $16.4M as of Q2 2026.
  • Raub Brock Capital Management sold 4,866 Eli Lilly shares in Q2 2026, an estimated $4.97M.
  • Eli Lilly made up 4.53% of Raub Brock Capital Management's portfolio in Q2 2026, its #3 holding.
  • Raub Brock Capital Management first reported a position in Eli Lilly in Q2 2022 and has held it in 17 quarters since.
  • Raub Brock Capital Management's Eli Lilly position peaked at $24M in Q3 2023.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Raub Brock Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.